Cerebrospinal fluid B cells do not predict multiple sclerosis progression
B cell subtypes in the cerebrospinal fluid (CSF) of multiple sclerosis (MS) patients are not predictors of disease progression, expanded disability status scale (EDSS) progression or conversion to clinical definite MS (CDMS), a recent longitudinal prospective study has shown.
Over a median follow-up period of 7.9 years, CSF samples were extracted from 40 clinically isolated syndrome (CIS), 27 relapsing remitting MS (RRMS), two secondary progressive MS (SPMS) and nine primary progressive MS (PPMS) patients. A control group of 40 patients with other neurological diseases (OND) was included.
Older age at baseline (odds ratio [OR], 1.7; 95 percent CI, 1.0 to 3.0; p=0.041) was the only significant prognostic factor for MS progression after comparing the SPMS and PPMS with the CIS and RRMS patients.
There were no significant associations found for sex (OR, 0.3; 0.0 to 3.8; p=0.380), duration of disease (OR, 1.3; 0.9 to 1.9; p=0.097), CD19+CD138- cells (OR, 0.0; 0.0 to 7.8; p=0.166) or CD19+CD138+ cells (OR, 0.5; 0.0 to 26.3; p=0.736).
Similarly, age at baseline (OR, 1.1; 1.0 to 1.1; p=0.012) was the only significant prognostic factor for EDSS progression. CD19+CD138- (OR, 0.1; 0.0 to 1.2; p=0.077) and CD19+CD138+ (OR, 1.6; 0.4 to 6.7; p=0.531) cells were not significantly correlated.
On the other hand, flow cytometry analysis showed that the majority of B cells in the CSF of MS patients were either CD19+CD138- mature B cells or CD19+CD138+ plasmablasts. At follow-up, the CSF composition of CIS, RRMS and SPMS patients were significantly different from the OND controls (p<0.001). PPMS CSF composition did not significantly differ from OND CSF composition.